Ligand is a high-growth company with economic rights to some of the world's most important medicines.
Ligand’s portfolio covers a diverse array of therapeutic areas, partners and underlying technologies with many products in late stage development.
Ligand’s investment in new technology has resulted in cutting-edge innovations that are making major drugs possible.
Ligand has multiple technologies and unpartnered programs available for out-licensing.
Jul 14, 2016 • 9:00 AM EDT
Ligand to Report Second Quarter Results on August 4th
Jul 8, 2016 • 9:00 AM EDT
Ligand Enters into OmniAb® Platform License Agreement with Gilead Sciences
Jun 30, 2016 • 4:02 PM EDT
Ligand Receives $4 Million from Expansion of Two OmniAb® License Agreements
Jun 22, 2016
See all events
Jun 1, 2016
May 11, 2016 • 2:20pm EDT
Las Vegas, NV
Aug 4, 2016 • 9:00am EDT
Mid Cap Biotech & Pharma
Number of Patent Applications:
FDA grants Merrimack fast track designation for seribantumab (MM-121) in non-small cell lung cancer https://t.co/sRKMXHcRGB
Ono Pharmaceutical receives marketing approval in Japan for Kyprolis https://t.co/lMRBS3ysJ9